(Q42234578)

English

Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein

scientific article published on 28 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Plasmodium vivax

0 references

0 references

Ricardo T. Fujiwara

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Oscar Bruna-Romero

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Mariana Oliveira Dias

object named as

Mariana Oliveira Dias

2

0 references

author name string

Ana Paula Morais Martins Almeida

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Carolina de Almeida Fagundes Vieira

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Carlos Chávez-Olórtegui

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ricardo Tostes Gazzineli

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Maurício Martins Rodrigues

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

28 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

2181-2187

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

A long neglected world malaria map: Plasmodium vivax endemicity in 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Vivax malaria: neglected and not benign

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Pyrethroid Resistance in Anopheles gambiae, in Bomi County, Liberia, Compromises Malaria Vector Control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Immunological properties of hepatitis B core antigen fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Plasmodium vivax malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium y

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.053

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2014.02.053

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42234578&oldid=1937405710"